Canada Polycystic Kidney Disease (APDKD) Market Analysis

Canada Polycystic Kidney Disease (APDKD) Market Analysis


$ 3999

Canada Polycystic Kidney Disease (APDKD) Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Polycystic Kidney Disease (APDKD) market is growing globally due to the he ADPKD market has experienced significant growth due to increased awareness, improved diagnostics, and advancements in treatment options. The market size is expected to expand further with the introduction of innovative therapies and the rising incidence of ADPKD. Johnson & Johnson Private Limited, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc, AbbVie Inc., Novartis AG, Taro Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company are the key global market players in polycystic kidney disease (APDKD) market.

ID: IN10CAPH380 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Riddhi Solanki

Buy Now

Canada Polycystic Kidney Disease (APDKD) Market Analysis Summary

Canada Polycystic Kidney Disease (APDKD) Market is valued at around $39.6 Mn in 2022 and is projected to reach $62.8 Mn by 2030, exhibiting a CAGR of 5.93% during the forecast period 2023-2030.

A genetic condition known as polycystic kidney disease (PKD) is characterized by the development of many cysts in the kidneys. The most prevalent type of PKD is autosomal dominant polycystic kidney disease (ADPKD). A multidisciplinary strategy is used to manage ADPKD, including the regulation of blood pressure, the management of symptoms, and the use of disease-modifying medicines. Angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs), and tolvaptan (a vasopressin V2 receptor antagonist) are currently available treatments for ADPKD. The creation of targeted medicines to halt the progression of disease, the investigation of combination medications, and the incorporation of precision medicine methods for individualized care.

Johnson & Johnson Private Limited, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc, AbbVie Inc., Novartis AG, Taro Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company are the key global market players in polycystic kidney disease (APDKD) market.

Market Dynamics

Market Growth Drivers

Increasing incidences of kidney failure, increasing disease awareness, increasing investment for healthcare infrastructure, technological developments in diagnostics, unmet medical needs including the need for disease-modifying therapies that can slow disease progression, drive research and development efforts in the field, rising Healthcare Expenditure, Collaborative Research and Development Efforts between Pharmaceutical companies, academic institutions, and research organizations and Favorable Regulatory Environment like orphan drug designation. All these factors act as market growth drivers.

Market Restraints

High cost associated with treatment, lack of skilled professionals, the complexity of the disease, limited treatment options, Limited Reimbursement Policies, and Limited Awareness and Diagnosis. All these factors act as market growth restraints.

Competitive Landscape

Key Players

  • Johnson & Johnson Private Limited
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Novartis AG
  • Taro Pharmaceutical Industries Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Canada Polycystic Kidney Disease (APDKD) Market

By Type

  • Autosomal Dominant Polycystic Kidney Disease
  • Autosomal Recessive Polycystic Kidney Disease
  • Others

By Treatment

  • Medication
  • Surgery
  • Others

By Diagnosis

  • Ultrasound
  • CT Scan
  • MRI Scan

By Route of Administration

  • Oral
  • Parenteral
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Ritu Baliya

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up